Quick Answer
ARTELO BIOSCIENCES, INC. reported Research And Development Expense of $5.42 million for the year ending 2025.
- ARTELO BIOSCIENCES, INC. showed a decrease of -9.5% in Research And Development Expense from 2024 to 2025.
- This data is from ARTELO BIOSCIENCES, INC.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2018 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2017: $33.1 thousand | Q1 2018: $647.5 thousand | Q2 2018: $236.8 thousand | Q4 2018: $184.0 thousand | Q1 2019: $490.0 thousand | Q2 2019: $184.2 thousand | Q4 2019: $666.9 thousand | Q1 2020: $721.3 thousand | Q2 2020: $258.7 thousand | Q4 2020: $595.0 thousand | Q1 2021: $663.4 thousand | Q1 2021: $307.0 thousand | Q2 2021: $951.2 thousand | Q2 2021: $970.0 thousand | Q3 2021: $1.03 million | Q4 2021: $1.27 million | Q4 2021: $1.94 million | Q1 2022: $464.0 thousand | Q2 2022: $1.06 million | Q3 2022: $1.08 million | Q1 2023: $1.24 million | Q2 2023: $752.0 thousand | Q3 2023: $1.59 million | Q1 2024: $1.51 million | Q2 2024: $1.69 million | Q3 2024: $325.0 thousand | Q1 2025: $1.38 million | Q2 2025: $1.87 million | Q3 2025: $1.28 million.
- Over the full 9 years of available data (2018 to 2025), ARTELO BIOSCIENCES, INC.'s Research And Development Expense has grown by 333.9%.
- Historical annual values: Fiscal year 2025: $5.42 million | Fiscal year 2024: $5.99 million | Fiscal year 2023: $5.70 million | Fiscal year 2022: $4.32 million | Fiscal year 2021: $3.78 million | Fiscal year 2021: $2.84 million | Fiscal year 2020: $1.92 million | Fiscal year 2019: $1.09 million | Fiscal year 2018: $1.25 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: